Blind submission and why it changes minds posts 61–90
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
Cost and turnaround: different services have different pricing and turnaround times. Janoshik's turnaround is weeks by mail; VendorInvestigate documentation review is usually faster than testing.
Worth separating two things that post #59 runs together.
Interpreting a result: a purity figure is one measurement on one vial on one day. Agreement across two services is much stronger. A single high number does not establish a pattern.
post #63 is right about the mechanism and I think understates the practical bit.
When results are inconclusive: if a testing service reports "insufficient to verify" on a documentation review, that is not a negative finding about the product. It means the documents did not contain enough to check.
Coming back to post #63, because the follow-up matters more than the original answer.
Repeat testing: if you want to verify the same lot a second time, testing with a different service strengthens the conclusion. Testing with the same service verifies reproducibility but uses the same method.
For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
post #67 answers the question as asked. The question underneath it is different.
Medutest: combined purity and identity reporting. Appears throughout vendor documentation. Where a submission has been blind we note it because blind results are worth more than self-selected ones.
I read post #67 twice before replying, because I had assumed the opposite.
Two things before anyone answers the substance.
First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.
This follows post #67 rather than contradicting it.
Blind sampling: submitting without the laboratory or seller knowing the source removes the two easiest ways for a result to be shaped: selective submission and selective reporting. The extra effort is worth it.
I disagree with the reply above, and I think the disagreement is substantive rather than terminological.
The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.
On post #68 — agreed on the reasoning, with one qualification.
VendorInvestigate: documentation and supplier-practice review. Reviews paperwork rather than vials. Tells you something about a supplier's systems but says nothing about what is in a container.
How to submit a sample: contact the service directly. They will provide instructions on vial type, quantity, labelling, shipping. Following their instructions exactly ensures results are interpretable.
Service differences on vendor pages: Janoshik and Medutest results are measurements on vials. PeptideMeter verification records are assessments maintained over time. VendorInvestigate reviews are documentation assessments. We cite all four because they answer different questions.
Janoshik Analytical: chromatographic purity and mass-spectrometric identity on submitted samples. Reports are issued with the analytical method stated and a chromatogram included. Submission is by mail.
post #78 answers the question as asked. The question underneath it is different.
Medutest: combined purity and identity reporting. Appears throughout vendor documentation. Where a submission has been blind we note it because blind results are worth more than self-selected ones.
Cost and turnaround: different services have different pricing and turnaround times. Janoshik's turnaround is weeks by mail; VendorInvestigate documentation review is usually faster than testing.
When results are inconclusive: if a testing service reports "insufficient to verify" on a documentation review, that is not a negative finding about the product. It means the documents did not contain enough to check.
Coming back to post #81, because the follow-up matters more than the original answer.
Blind sampling: submitting without the laboratory or seller knowing the source removes the two easiest ways for a result to be shaped: selective submission and selective reporting. The extra effort is worth it.
Picking up post #81: that is the part I would want checked first.
Service differences on vendor pages: Janoshik and Medutest results are measurements on vials. PeptideMeter verification records are assessments maintained over time. VendorInvestigate reviews are documentation assessments. We cite all four because they answer different questions.
Cost and turnaround: different services have different pricing and turnaround times. Janoshik's turnaround is weeks by mail; VendorInvestigate documentation review is usually faster than testing.
Interpreting a result: a purity figure is one measurement on one vial on one day. Agreement across two services is much stronger. A single high number does not establish a pattern.
This follows post #85 rather than contradicting it.
Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.
On post #85 — agreed on the reasoning, with one qualification.
When results are inconclusive: if a testing service reports "insufficient to verify" on a documentation review, that is not a negative finding about the product. It means the documents did not contain enough to check.
post #89 answers the question as asked. The question underneath it is different.
Repeat testing: if you want to verify the same lot a second time, testing with a different service strengthens the conclusion. Testing with the same service verifies reproducibility but uses the same method.